Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT03085056
- Phase
- EARLY_PHASE1
- Status
- Active Not Recruiting
Conditions
- Anaplastic Thyroid Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Trametinib — DRUGtrametinib orally 2mg daily during each 4 week cycle
- Paclitaxel — DRUGpaclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks
Study Details
The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.
Key Dates
- Start date
- Mar 15, 2017
- Status verified
- Jul 2025
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 13 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Trametinib in Combination With PaclitaxelPatients will receive paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks, which is a standard regimen in the treatment of anaplastic thyroid cancer, in combination with trametinib 2mg daily during each 4 week cycle.
Primary Outcome Measure
Progression-Free Survival (PFS) [ Time Frame: 6 months ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | 07920 | - |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | New Jersey | 07748 | - |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | 07645 | - |
| Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities) | Commack | New York | 11725 | - |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York | 10604 | - |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | - |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale | New York | 11553 | - |
Find similar trials in Basking Ridge, NJ
By research site
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)· Commack, NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center· New York, NY
Related Studies
- XL092 and Cemiplimab in BRAF WT Thyroid CancerPHASE1 · Recruiting · UNC Lineberger Comprehensive Cancer Center · Boston, Massachusetts
- Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerPHASE2 · Not Yet Recruiting · M.D. Anderson Cancer Center · Houston, Texas